{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:17:39Z","timestamp":1785860259143,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA116477"],"award-info":[{"award-number":["R01 CA116477"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA187037"],"award-info":[{"award-number":["R01 CA187037"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA239124"],"award-info":[{"award-number":["R01 CA239124"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00259-023-06528-2","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T07:02:11Z","timestamp":1702882931000},"page":"1409-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma\u2014a proof of concept study"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3423-6401","authenticated-orcid":false,"given":"Ioanna","family":"Liatsou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1516-1854","authenticated-orcid":false,"given":"Yingli","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-6166","authenticated-orcid":false,"given":"Mahmud","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-7841","authenticated-orcid":false,"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-0873","authenticated-orcid":false,"given":"Allison","family":"Cartee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-6940","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-6154","authenticated-orcid":false,"given":"Yong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-9850","authenticated-orcid":false,"given":"Jeffrey","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0875-5323","authenticated-orcid":false,"given":"Dara L.","family":"Kraitchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4553-2866","authenticated-orcid":false,"given":"George","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"6528_CR1","doi-asserted-by":"crossref","unstructured":"Markham A. Naxitamab: first approval. Drugs. 2021.","DOI":"10.1007\/s40265-021-01467-4"},{"key":"6528_CR2","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1158\/0008-5472.CAN-18-3340","volume":"79","author":"ER Butch","year":"2019","unstructured":"Butch ER, Mead PE, Amador Diaz V, Tillman H, Stewart E, Mishra JK, et al. Positron emission tomography detects in vivo expression of disialoganglioside GD2 in mouse models of primary and metastatic osteosarcoma. Cancer Res. 2019;79:3112\u201324.","journal-title":"Cancer Res"},{"key":"6528_CR3","doi-asserted-by":"crossref","unstructured":"Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020.","DOI":"10.3389\/fonc.2020.01000"},{"key":"6528_CR4","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a National Cancer Institute Pilot Project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323\u201337.","journal-title":"Clin Cancer Res"},{"key":"6528_CR5","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/jvim.15557","volume":"33","author":"C Parachini-Winter","year":"2019","unstructured":"Parachini-Winter C, Curran KM, Pellin M, Laver T, Hanot C, Vernier TH, et al. Cutaneous and subcutaneous metastasis of appendicular osteosarcoma in dogs: 20 cases. J Vet Intern Med. 2019;33:2200\u20138.","journal-title":"J Vet Intern Med"},{"key":"6528_CR6","doi-asserted-by":"crossref","unstructured":"Sheng G, Gao Y, Yang Y, Wu H. Osteosarcoma and metastasis. Frontiers in Oncology. 2021.","DOI":"10.3389\/fonc.2021.780264"},{"key":"6528_CR7","doi-asserted-by":"crossref","unstructured":"Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CS. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 2017;59.","DOI":"10.1186\/s13028-017-0341-9"},{"key":"6528_CR8","doi-asserted-by":"crossref","unstructured":"Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer. 2009;115.","DOI":"10.1002\/cncr.24121"},{"key":"6528_CR9","doi-asserted-by":"crossref","unstructured":"Saam DE, Liptak JM, Stalker MJ, Chun R. Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996\u20132006). J Am Vet Med Assoc. 2011;238.","DOI":"10.2460\/javma.238.2.195"},{"key":"6528_CR10","doi-asserted-by":"crossref","unstructured":"Makielski KM, Mills LJ, Sarver AL, Henson MS, Spector LG, Naik S, et al. Risk factors for development of canine and human osteosarcoma: a comparative review. Vet Sci. 2019.","DOI":"10.3390\/vetsci6020048"},{"key":"6528_CR11","doi-asserted-by":"crossref","unstructured":"Kawashima H. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Sci World J. 2014.","DOI":"10.1155\/2014\/492061"},{"key":"6528_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson SM, Carrasquillo JA, Cheung N-KV, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347\u201360.","journal-title":"Nat Rev Cancer"},{"key":"6528_CR13","doi-asserted-by":"crossref","unstructured":"Sgouros G. Radiopharmaceutical therapy. Health Phys. 2019;116.","DOI":"10.1097\/HP.0000000000001000"},{"key":"6528_CR14","doi-asserted-by":"publisher","unstructured":"Fu Y, Yu J, Liatsou I, Du Y, Josefsson A, Nedrow JR, et al. Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:4382\u201393.\u00a0https:\/\/doi.org\/10.1007\/s00259-022-05888-5.","DOI":"10.1007\/s00259-022-05888-5"},{"key":"6528_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"6528_CR16","doi-asserted-by":"crossref","unstructured":"Vaziri B, Wu H, Dhawan AP, Du P, Howell RW. MIRD Pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med. 2014;55:1557 LP \u2013 1564.","DOI":"10.2967\/jnumed.113.131037"},{"key":"6528_CR17","doi-asserted-by":"crossref","unstructured":"Pandit-Taskar N. Targeted radioimmunotherapy and theranostics with alpha emitters. J Med Imaging Radiat Sci. 2019;50.","DOI":"10.1016\/j.jmir.2019.07.006"},{"key":"6528_CR18","doi-asserted-by":"crossref","unstructured":"AU - Ishiyama S, AU - Kissel C, AU - Guo X, AU - Howard A, AU - Saeki H, AU - Ito T, et al. A syngeneic orthotopic osteosarcoma Sprague Dawley rat model with amputation to control metastasis rate. JoVE. 2021;e62139.","DOI":"10.3791\/62139"},{"key":"6528_CR19","doi-asserted-by":"crossref","unstructured":"Liatsou I, Josefsson A, Yu J, Li Z, Davis K, Brayton C, et al. Early normal tissue effects and bone marrow relative biological effectiveness for an actinium 225\u2013labeled HER2\/neu-targeting antibody. International Journal of Radiation Oncology*Biology*Physics [Internet]. 2023; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623005862.","DOI":"10.1016\/j.ijrobp.2023.06.003"},{"key":"6528_CR20","doi-asserted-by":"crossref","unstructured":"Demidenko E. Three endpoints of in vivo tumour radiobiology and their statistical estimation. Int J Radiat Biol. 2010.","DOI":"10.3109\/09553000903419304"},{"key":"6528_CR21","doi-asserted-by":"crossref","unstructured":"Spasov NJ, Dombrowski F, Lode HN, Spasova M, Ivanova L, Mumdjiev I, et al. First-line anti-GD2 therapy combined with consolidation chemotherapy in 3 patients with newly diagnosed metastatic Ewing sarcoma or Ewing-like sarcoma. J Pediatr Hematol Oncol. 2022;44.","DOI":"10.1097\/MPH.0000000000002488"},{"key":"6528_CR22","doi-asserted-by":"crossref","unstructured":"Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, et al. Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target Oncol. 2018.","DOI":"10.1007\/s11523-018-0550-9"},{"key":"6528_CR23","doi-asserted-by":"crossref","unstructured":"Anderson PM, Scott J, Parsai S, Zahler S, Worley S, Shrikanthan S, et al. 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open. 2020;5.","DOI":"10.1136\/esmoopen-2019-000635"},{"key":"6528_CR24","doi-asserted-by":"crossref","unstructured":"Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. Molecules. 2022.","DOI":"10.3390\/molecules27165231"},{"key":"6528_CR25","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1038\/s41467-022-33110-5","volume":"13","author":"L De Chiara","year":"2022","unstructured":"De Chiara L, Conte C, Semeraro R, Diaz-Bulnes P, Angelotti ML, Mazzinghi B, et al. Tubular cell polyploidy protects from lethal acute kidney injury but promotes consequent chronic kidney disease. Nat Commun. 2022;13:5805.","journal-title":"Nat Commun"},{"key":"6528_CR26","unstructured":"Curtis Seely J, Brix A. Kidney, renal tubule \u2013 regeneration [Internet]. Available from: https:\/\/ntp.niehs.nih.gov\/nnl\/urinary\/kidney\/rtregen\/."},{"key":"6528_CR27","doi-asserted-by":"publisher","first-page":"8308","DOI":"10.1038\/s41598-018-26693-x","volume":"8","author":"A Oda","year":"2018","unstructured":"Oda A, Tezuka T, Ueno Y, Hosoda S, Amemiya Y, Notsu C, et al. Niche-induced extramedullary hematopoiesis in the spleen is regulated by the transcription factor Tlx1. Sci Rep. 2018;8:8308.","journal-title":"Sci Rep"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06528-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:06:14Z","timestamp":1711019174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06528-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["6528"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06528-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal protocols were approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine. Client-owned dogs with confirmed metastatic OS were recruited from owners with written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}